Arcus Biosciences (RCUS) FCF Margin (2017 - 2026)
Arcus Biosciences (RCUS) posted quarterly FCF Margin of 811.76% for Q1 2026, down 33676.0% year-over-year from N/an in Q1 2025, and down 121.39% quarter-over-quarter from 366.67% in Q4 2025.
Arcus Biosciences (RCUS) FCF Margin (2017 - 2026) Analysis & Trends
Arcus Biosciences' FCF Margin history runs 10 years deep, the most recent figure standing at 811.76% for Q1 2026.
- In Q1 2026, FCF Margin fell 33676.0% year-over-year to 811.76%; the TTM figure through Mar 2026 stood at 207.2% (down 1004.0% YoY), while the FY2025 annual figure was 195.95%, down 13859.0% from the prior year.
- FCF Margin for Q1 2026 stood at 811.76%, down from 366.67% in the prior quarter.
- The five-year high for FCF Margin was 3616.67% in Q1 2022, with the low at 811.76% in Q1 2026.
- The 5-year median for FCF Margin is 248.72% (2024), against an average of 73.72%.
- The sharpest annual moves came in 2022 and 2023: FCF Margin surged 434703 bps in 2022, then tumbled 404067 bps in 2023.
- Arcus Biosciences' FCF Margin stood at 211.76% in 2022, then tumbled by 237 bps to 714.29% in 2023, then surged by 49 bps to 361.54% in 2024, then fell by 1 bps to 366.67% in 2025, then tumbled by 121 bps to 811.76% in 2026.
- Business Quant data shows RCUS's FCF Margin at 811.76% in Q1 2026, 366.67% in Q4 2025, and 373.08% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Arcus Biosciences | 3.74 Bn | 3.04 Bn | - | -290.24% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -290.24% |
| Mar 31, 2026 | -811.76% |
| Dec 31, 2025 | -366.67% |
| Sep 30, 2025 | -373.08% |
| Jun 30, 2025 | -83.13% |
| Mar 31, 2025 | -475.00% |
| Dec 31, 2024 | -361.54% |
| Sep 30, 2024 | 95.83% |
| Jun 30, 2024 | -248.72% |
| Mar 31, 2024 | -2.07% |
| Dec 31, 2023 | -714.29% |
| Sep 30, 2023 | -209.38% |
| Jun 30, 2023 | -196.55% |
| Mar 31, 2023 | -424.00% |
| Dec 31, 2022 | -211.76% |
| Sep 30, 2022 | -254.55% |
| Jun 30, 2022 | -233.33% |
| Mar 31, 2022 | 3,616.67% |
| Dec 31, 2021 | -17.01% |
| Sep 30, 2021 | -621.85% |